Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

被引：14

作者：

Santoni, Matteo ^{[1
]}

Massari, Francesco ^{[2
,57
]}

Myint, Zin W. ^{[3
]}

Iacovelli, Roberto ^{[4
]}

Pichler, Martin ^{[5
]}

Basso, Umberto ^{[6
]}

Kopecky, Jindrich ^{[7
]}

Kucharz, Jakub ^{[8
]}

Buti, Sebastiano ^{[9
]}

Salfi, Alessia ^{[10
]}

Buettner, Thomas ^{[11
]}

De Giorgi, Ugo ^{[12
]}

Kanesvaran, Ravindran ^{[13
]}

Fiala, Ondrej ^{[14
]}

Grande, Enrique ^{[15
]}

Zucali, Paolo Andrea ^{[16
,17
]}

Fornarini, Giuseppe ^{[18
]}

Bourlon, Maria T. ^{[19
]}

Scagliarini, Sarah ^{[20
]}

Molina-Cerrillo, Javier ^{[21
]}

Aurilio, Gaetano ^{[22
]}

Matrana, Marc R. ^{[23
]}

Pichler, Renate ^{[24
]}

Cattrini, Carlo ^{[25
]}

Buechler, Tomas ^{[26
]}

Seront, Emmanuel ^{[27
]}

Calabro, Fabio ^{[28
]}

Pinto, Alvaro ^{[29
]}

Berardi, Rossana ^{[30
]}

Zgura, Anca ^{[31
]}

Mammone, Giulia ^{[32
]}

Ansari, Jawaher ^{[33
]}

Atzori, Francesco ^{[34
]}

Chiari, Rita ^{[35
]}

Zakopoulou, Roubini ^{[36
]}

Caffo, Orazio ^{[37
]}

Procopio, Giuseppe ^{[38
,39
]}

Bassanelli, Maria ^{[40
]}

Zampiva, Ilaria ^{[41
]}

Messina, Carlo ^{[42
]}

Kueronya, Zsofia ^{[43
]}

Mosca, Alessandra ^{[44
]}

Bhuva, Dipen ^{[45
]}

Vau, Nuno ^{[46
]}

Incorvaia, Lorena ^{[47
]}

Rebuzzi, Sara Elena ^{[48
,49
]}

Roviello, Giandomenico ^{[50
]}

Zabalza, Ignacio Ortego ^{[15
]}

Rizzo, Alessandro ^{[51
]}

Mollica, Veronica ^{[2
]}

机构：

[1] Macerata Hosp, Oncol Unit, Macerata, Italy

[2] IRCCS Azienda Ospedaliero Univ Bologna, Med Oncol, I-40138 Bologna, Italy

[3] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA

[4] Fdn Policlin Univ Agostino Gemelli IRCCS, UOC Oncol Med, Rome, Italy

[5] Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria

[6] Ist Oncol Veneto IOV, Oncol Unit 3, IRCCS, Padua, Italy

[7] Univ Hosp Hradec Kralove, Dept Clin Oncol & Radiotherapy, Hradec Kralove 50005, Czech Republic

[8] Mar Sklodowska Curie Natl Res Inst Oncol, Dept Uro oncol, Warsaw, Poland

[9] Univ Parma, Univ Hosp Parma, Dept Med & Surg, Med Oncol Unit, Parma, Italy

[10] Univ Hosp Pisa, Oncol Unit 2, Pisa, Italy

[11] Univ Hosp Bonn UKB, Dept Radiol, Bonn, Germany

[12] IRCCS, Ist Romagnolo Studio Tumori IRST Dino Amadori, Dept Med Oncol, Meldola, Italy

[13] Natl Canc Ctr Singapore, Div Radiat Oncol, Singapore, Singapore

[14] Charles Univ Prague, Univ Hosp Pilsen, Fac Med Pilsen, Dept Pneumol & Phthisiol, Plzen, Czech Republic

[15] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain

[16] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[17] IRCCS Humanitas Res Hosp, Dept Urol, Milan, Italy

[18] IRCCS Osped Policlin San Martino, Genoa, Italy

[19] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Hematol & Oncol, Mexico City, Mexico

[20] UOC Oncol, ASLNA3 Frattamaggiore Napoli, Naples, Italy

[21] Hosp Ramon & Cajal, Dept Med Oncol, Madrid, Spain

[22] European Inst Oncol IRCCS, Med Oncol Div Urogenital & Head & Neck Tumours, IEO, Milan, Italy

[23] Ochsner Med Ctr, Dept Internal Med, New Orleans, LA 70121 USA

[24] Med Univ Innsbruck, Dept Urol, Innsbruck, Austria

[25] Maggiore Car Univ Hosp, Novara, Italy

[26] Charles Univ & Thomayer Univ Hosp, Fac Med 1, Dept Oncol, Prague, Czech Republic

[27] Ctr Hospitalier Univ Ambroise Pare, Mons, Belgium

[28] San Camillo Forlanini Hosp, Dept Radiat Oncol, Rome, Italy

[29] La Paz Univ Hosp, Med Oncol Dept, Madrid, Spain

[30] Univ Polytecn Marche, Dept Urol, AOU Ospedali Riuniti, Ancona, Italy

[31] Carol Davila Univ Med & Pharm, Prof Dr Alexandru Trestioreanu Inst Oncol, Dept Oncol Radiotherapy, Bucharest, Romania

[32] Sapienza Univ Rome, Dept Radiol Oncol & Anatomo Pathol Sci, Rome, Italy

[33] Tawam Hosp, Dept Med Oncol, Al Ain, U Arab Emirates

[34] Univ Cagliari, Med Oncol Dept, Cagliari, Italy

[35] Azienda Ospedaliera Ospedali Riuniti Marche Nord, Oncol Unit, I-61122 Pesaro, Italy

[36] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Sch Med, Dept Internal Med 2, Athens, Greece

[37] St Chiara Hosp, Med Oncol Unit, Trento, Italy

[38] Fdn IRCCS Ist Nazl Tumori, Dipartimento Oncol Med, Milan, Italy

[39] Osped Maggiore La Carita, SCDU Oncol Med, Novara, Italy

[40] IRCCS Regina Elena Natl Canc Inst, Med Oncol 1, Rome, Italy

[41] Univ Verona, Univ Hosp & Trust Verona, Dept Vasc Surg, Sch Med, Verona, Italy

[42] Oncol Unit, A, RNAS Civ, Palermo, Italy

[43] Natl Inst Oncol, Dept Genitourinary Med Oncol & Clin Pharmacol, Budapest, Hungary

[44] IRCCS, FPO, Candiolo Canc Inst, Turin, Italy

[45] Army Hosp Res & Referral, Dept Med Oncol, New Delhi, India

[46] Champalimaud Clin Ctr, Radiol Dept, Lisbon, Portugal

[47] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Palermo, Italy

[48] Osped San Paolo, I-17100 Savona, Italy

[49] Univ Genoa, IRCCS Osped Policlin San Martino, Dept Internal Md & Med Specialties Di M I, Largo Rosanna Benzi 10, I-16132 Genoa, Italy

[50] Univ Florence, Dept Hlth Sci, Sect Clin Pharmacol & Oncol, Florence, Italy

来源：

CLINICAL GENITOURINARY CANCER | 2023年 / 21卷 / 05期

关键词：

Immunotherapy; Immunocombo; mRCC; NCT05287464; Obesity; Survival; Tumor Response; OBESITY; MECHANISMS; SUNITINIB; NIVOLUMAB;

D O I：

10.1016/j.clgc.2023.03.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO + IO) or a combination of immuno-oncology drug and a tyrosine kinase inhibitors (TKI) as first -line therapy for metastatic renal cell carcinoma (mRCC). Patients and Methods: Medical records of patients with documented mRCC treated by immuno-oncology combinations were reviewed at 47 institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (OS), and overall clinical benefit (OCB), defined as the sum of the rate of partial/complete responses and stable disease. Univariate and multivariate analyses were used to explore the association of variables of interest with survival. Results: A total of 675 patients were included; BMI was > 25 kg/m(2) in 345 patients (51%) and was associated with improved OS (55.7 vs. 28.4 months, P < .001). The OCB of patients with BMI > 25 kg/m(2) versus those with BMI <= 25 kg/m(2) was significantly higher only in patients with nonclear cell histology (81% vs. 65%, P = .011), and patients with liver metastases (76% vs. 58%, P = .007), Neutrophil to lymphocyte ratio > 4 (77% vs 62%, P = .022) or treated by nivolumab plus ipilimumab (77% vs. 64%, P = .044). In the BMI <= 25 kg/m(2) subgroup, significant differences were found between patients with NLR > 4 versus <= 4 (62% vs. 82%, P = .002) and patients treated by IO + IO versus IO + TKIs combinations (64% vs. 83%, P = .002). Conclusion: Our study suggests that the prognostic significance and the association of BMI with treatment outcome varies across clinico-pathological mRCC subgroups.

引用

页码：E309 / U12

页数：12

共 39 条

[1] The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications [J].

Aurilio, Gaetano ;

Piva, Francesco ;

Santoni, Matteo ;

Cimadamore, Alessia ;

Sorgentoni, Giulia ;

Lopez-Beltran, Antonio ;

Cheng, Liang ;

Battelli, Nicola ;

Nole, Franco ;

Montironi, Rodolfo .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (22)

[2] Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study [J].

Basso, Umberto ;

Paolieri, Federico ;

Rizzo, Mimma ;

De Giorgi, Ugo ;

Bracarda, Sergio ;

Antonuzzo, Lorenzo ;

Atzori, Francesco ;

Carteni, Giacomo ;

Procopio, Giuseppe ;

Fratino, Lucia ;

D'Arcangelo, Manolo ;

Fornarini, Giuseppe ;

Zucali, Paolo ;

Cusmai, Antonio ;

Santoni, Matteo ;

Pipitone, Stefania ;

Carella, Claudia ;

Panni, Stefano ;

Deppieri, Filippo Maria ;

Zagonel, Vittorina ;

Tortora, Giampaolo .

CANCERS, 2022, 14 (09)

[3] Obesity: global epidemiology and pathogenesis [J].

Blueher, Matthias .

NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (05) :288-298

[4] Obesity: a certain and avoidable cause of cancer [J].

Campbell, Peter T. .

LANCET, 2014, 384 (9945) :727-728

[5] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[6] Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study [J].

Cortellini, Alessio ;

De Giglio, Andrea ;

Cannita, Katia ;

Cortinovis, Diego L. ;

Cornelissen, Robin ;

Baldesarri, Cinzia ;

Giusti, Raffaele ;

D'Argento, Ettore ;

Grossi, Francesco ;

Santoni, Matteo ;

Catino, Annamaria ;

Berardi, Rossana ;

Sforza, Vincenzo ;

Rossi, Giovanni ;

Antonuzzo, Lorenzo ;

Di Noia, Vincenzo ;

Signorelli, Diego ;

Gelibter, Alain ;

Occhipinti, Mario Alberto ;

Follador, Alessandro ;

Rastelli, Francesca ;

Chiari, Rita ;

Gravara, Luigi Della ;

Inno, Alessandro ;

De Tursi, Michele ;

Di Marino, Pietro ;

Mansueto, Giovanni ;

Zoratto, Federica ;

Filetti, Marco ;

Montrone, Michele ;

Citarella, Fabrizio ;

Pensieri, Maria Vittoria ;

Russano, Marco ;

Cantini, Luca ;

Nigro, Olga ;

Leonetti, Alessandro ;

Bordi, Paola ;

Minuti, Gabriele ;

Landi, Lorenza ;

De Toma, Alessandro ;

Donisi, Clelia ;

Ricciardi, Serena ;

Migliorino, Maria Rita ;

Napoli, Valerio Maria ;

Leone, Gianmarco ;

Metro, Giulio ;

Banna, Giuseppe L. ;

Friedlaender, Alex ;

Addeo, Alfredo ;

Ficorella, Corrado .

THORACIC CANCER, 2021, 12 (06) :880-889

[7] Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects [J].

Cortellino, Salvatore ;

Raveane, Alessandro ;

Chiodoni, Claudia ;

Delfanti, Gloria ;

Pisati, Federica ;

Spagnolo, Vanessa ;

Visco, Euplio ;

Fragale, Giuseppe ;

Ferrante, Federica ;

Magni, Serena ;

Iannelli, Fabio ;

Zanardi, Federica ;

Bertolini, Francesco ;

Dellabona, Paolo ;

Colombo, Mario P. ;

Tripodo, Claudio ;

Longo, Valter D. .

CELL REPORTS, 2022, 40 (08)

[8] The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis [J].

Dai, Linzheng ;

Jin, Bo ;

Liu, Tingting ;

Chen, Jun ;

Li, Guang ;

Dang, Jun .

ECLINICALMEDICINE, 2021, 38

[9] Diet-microbiome interactions in cancer treatment: Opportunities and challenges for precision nutrition in cancer [J].

Greathouse, K. Leigh ;

Wyatt, Madhur ;

Johnson, Abigail J. ;

Toy, Eugene P. ;

Khan, Joetta M. ;

Dunn, Kelly ;

Clegg, Deborah J. .

NEOPLASIA, 2022, 29

[10] Obesity: a perfect storm for carcinogenesis [J].

Harris, Benjamin H. L. ;

Macaulay, Valentine M. ;

Harris, David A. ;

Klenerman, Paul ;

Karpe, Fredrik ;

Lord, Simon R. ;

Harris, Adrian L. ;

Buffa, Francesca M. .

CANCER AND METASTASIS REVIEWS, 2022, 41 (03) :491-515

← 1 2 3 4 →